Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party (Q57796234)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party	article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Brentuximab vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation: A report from the EBMT Lymphoma Working Party (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

stem cell transplantation

1 reference

based on heuristic

inferred from title

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

José Luis Díez-Martín

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

David Michonneau

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Gonzalo Gutiérrez-García

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

6

object named as

Didier Blaise

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

author name string

Ali Bazarbachi

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Ariane Boumendil

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Hervé Finel

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Mohamad Mohty

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Luca Castagna

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Karl S Peggs

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Boris Afanasyev

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Paolo Corradini

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Stephen Robinson

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Francesca Bonifazi

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Ibrahim Yakoub-Agha

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Zafer Gülbas

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Adrian Bloor

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Jeremy Delage

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Albert Esquirol

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Ram Malladi

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Christof Scheid

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Jean El-Cheikh

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Hervé Ghesquières

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Silvia Montoto

24

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Peter Dreger

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

language of work or name

0 references

publication date

23 October 2018

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

125

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

90-98

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: a case-control study. Société Francaise de Greffe de Moelle.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: results of a spanish prospective cooperative protocol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Revised response criteria for malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of CD30 in patients with acute graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.31755

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.31755

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30351488%20AND%20SRC:MED&resulttype=core&format=json

30 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57796234&oldid=1998109024"